AG真人官方

STOCK TITAN

Icecure Medical Ltd. SEC Filings

ICCM NASDAQ

Welcome to our dedicated page for Icecure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Clinical trial costs, FDA milestones buried in R&D tables, and cash-burn details all hide inside IceCure Medical鈥檚 (ICCM) SEC reports鈥攁nd some filings top 200 pages. For anyone tracking the company鈥檚 liquid-nitrogen cryoablation platform, overlooking a single line about a pivotal study or financing tranche can upend an investment thesis overnight.

Stock Titan鈥檚 AI fixes that by converting every new EDGAR submission into a concise, plain-English brief. Need the IceCure Medical quarterly earnings report 10-Q filing or the latest IceCure Medical insider trading Form 4 transactions before the bell? Our engine tags ProSense revenue, clinical-trial spending, and regulatory timelines instantly. AG真人官方-time alerts on IceCure Medical Form 4 insider transactions real-time show how executives act when key data readouts approach.

Navigate faster with:

  • 10-K annual report鈥攐ur tool delivers an IceCure Medical annual report 10-K simplified, highlighting cash runway, patent life, and cryotherapy market share.
  • 8-K material events鈥攇别迟 IceCure Medical 8-K material events explained, from FDA clearances to strategic partnerships.
  • Proxy statements鈥拦别惫颈别飞 IceCure Medical proxy statement executive compensation to gauge incentive alignment.
  • Form 4鈥攖谤补肠办 IceCure Medical executive stock transactions Form 4 and spot buying or selling patterns with ease.

Common questions like 鈥淗ow do I read IceCure鈥檚 10-K?鈥� or 鈥淲hat does this 8-K mean for upcoming trials?鈥� are answered right on the document page, ensuring you鈥檙e understanding IceCure Medical SEC documents with AI instead of deciphering legal jargon.

From IceCure Medical earnings report filing analysis to pipeline risk assessment, every disclosure is indexed, summarized, and updated the moment it hits EDGAR鈥攕o you make decisions backed by complete, current information.

Rhea-AI Summary

Form 144 filing for LendingClub Corporation (LC) discloses that Chief Executive Officer Scott C. Sanborn intends to sell up to 10,500 common shares through Morgan Stanley Smith Barney on or after 3 July 2025. At the recent market price used in the filing, the transaction is valued at $130,725. The proposed sale represents roughly 0.01 % of the 114.2 million shares outstanding, thus having minimal dilutive impact.

Sanborn has already executed a series of Rule 10b5-1 programmed sales over the last three months, disposing of 31,500 shares in six equal blocks of 5,250 shares, generating aggregate gross proceeds of 鈮� $327,806. All shares being sold were originally acquired as restricted stock units on 25 Nov 2018.

Investors typically monitor Form 144 filings as an indicator of insider sentiment. While the dollar value is modest relative to Sanborn鈥檚 presumed total holdings and LC鈥檚 market capitalization, continued insider selling can create incremental supply and may be interpreted as a bearish signal if it persists or accelerates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

IceCure Medical Ltd. (Nasdaq: ICCM) filed a Free Writing Prospectus (FWP) dated 25 June 2025 in connection with its pending Form F-1 registration. The document promotes ProSense庐, a liquid-nitrogen cryoablation system designed to treat benign and malignant tumors through a minimally invasive freezing procedure.

Regulatory footing: ProSense already holds FDA 510(k) clearance for kidney, liver, neurology and fibroadenoma indications, CE mark in Europe and approvals in 15 other countries including China, Brazil and India. A De Novo FDA decision for early-stage, low-risk T1 breast cancer is expected after the agency reviews IceCure鈥檚 post-market study plan; an FDA advisory panel voted favorably on benefit-risk in November 2024. IceCure鈥檚 next-generation XSense platform has separate 510(k) clearance, with a soft commercial launch targeted for Q1 2026.

Clinical evidence: The U.S. ICE3 trial (194 patients, 19 sites) showed a 96.8 % local-recurrence-free rate when ProSense was followed by endocrine therapy, no serious device-related adverse events and 100 % patient & physician cosmetic satisfaction over five years. Independent external studies reportedly corroborate these findings.

Market context: Global tumor-ablation spend is projected to rise from US$1.0 bn in 2021 to US$2.4 bn in 2028, driven by demand for less-invasive options. In 2025 the U.S. addressable cryoablation market includes about 317 k new invasive breast-cancer cases and significant kidney, liver and lung cancer populations. IceCure owns 54 patents and has secured numerous distribution agreements.

Risks & next steps: The registration statement is not yet effective; investments can only be made via the final prospectus. Marketing expansion, reimbursement upgrades beyond the current CPT III code and additional clinical studies remain forward-looking objectives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
prospectus
Rhea-AI Summary

IceCure Medical Ltd. (NASDAQ: ICCM) filed a Form 6-K on 25 June 2025 reporting that it has furnished a press release entitled 鈥淚ceCure Announces Record Date for Rights Offering for Up to $10 Million.鈥� The press release, provided as Exhibit 99.1, is incorporated by reference into the company鈥檚 existing registration statements on Forms F-3 (Nos. 333-258660 & 333-267272) and S-8 (Nos. 333-270982, 333-264578, 333-262620 & 333-281587). The filing contains no financial statements, earnings data or detailed terms of the rights offering.

The company indicates only that a record date has been set for shareholders to participate in a rights offering of up to $10 million. If completed, this capital raise would provide additional liquidity while allowing existing shareholders to maintain proportional ownership by exercising their rights. However, subscription price, ratio, and expected closing date are not disclosed in this document. The report was signed by Chief Executive Officer Eyal Shamir.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
current report
-
Rhea-AI Summary

IceCure Medical Ltd. (ICCM) has filed Amendment No. 1 to its Form F-1 to launch a non-transferable rights offering that could raise up to US$10 million. Existing holders of the company鈥檚 ordinary shares as of the July 9, 2025 record date will receive one subscription right for every share owned. Each right allows the purchase of 0.1703 of a Unit at a subscription price of US$1.00 per Unit. A full Unit comprises one ordinary share and one five-year warrant exercisable at US$1.00. Because 0.1703 of a Unit is issued per right, shareholders must aggregate at least six rights to obtain one complete Unit; holders of fewer than six shares will be unable to participate.

The subscription period runs from July 10 to 5:00 p.m. ET on July 28, 2025. Unexercised rights will expire worthless unless the company extends the offering. Investors who fully exercise their basic rights may request additional Units under an over-subscription privilege, subject to proration.

Capital Structure: If fully subscribed, IceCure will issue up to 10 million Units consisting of either 10 million ordinary shares or, at investors鈥� option to avoid ownership limits, 10 million pre-funded warrants (exercise price US$0.0001) plus 10 million accompanying warrants. All warrants carry a call feature that can be triggered once ProSense breast-cancer marketing authorization is publicly announced and the share VWAP equals or exceeds 300 % of the exercise price for 30 consecutive trading days.

Back-stop Commitment: Epoch Partner Investments Limited, already holding 44.04 % of IceCure鈥檚 shares, has provided a standby commitment to purchase up to US$5 million of Units through basic and over-subscription privileges.

Use of Proceeds: Net proceeds, together with existing cash and investments, are earmarked to repay a Bridge Loan ("Loan Amount") and for general corporate and working-capital purposes.

Maxim Group LLC will act as dealer-manager on a best-efforts basis, and Broadridge Corporate Issuer Solutions, LLC is the subscription agent holding investor funds in escrow until completion or cancellation of the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
registration

FAQ

What is the current stock price of Icecure Medical Ltd. (ICCM)?

The current stock price of Icecure Medical Ltd. (ICCM) is $1.055 as of July 3, 2025.

What is the market cap of Icecure Medical Ltd. (ICCM)?

The market cap of Icecure Medical Ltd. (ICCM) is approximately 59.6M.

What is the core business of IceCure Medical Ltd?

IceCure Medical Ltd focuses on developing and marketing liquid nitrogen-based cryoablation systems. The company offers minimally invasive solutions for the treatment of a range of tumors, including those in the breast, kidney, bone, and lung.

How does cryoablation technology work?

Cryoablation involves using liquid nitrogen to freeze and destroy tumor tissues. IceCure鈥檚 technology creates large lethal zones that effectively target both benign and malignant tumors while reducing the need for invasive surgical procedures.

Which clinical indications are addressed by IceCure鈥檚 products?

The company鈥檚 cryoablation systems are primarily used for the treatment of tumors in areas such as the breast, kidney, bone, and lung. Their products are designed to offer safe and effective alternatives to traditional surgical interventions.

What sets IceCure鈥檚 technology apart from traditional surgical methods?

IceCure鈥檚 minimally invasive approach reduces surgical risks, shortens recovery times, and minimizes patient discomfort. The technology is supported by comprehensive clinical research, demonstrating outcomes that are comparable to conventional surgery but with fewer complications.

How does IceCure validate the efficacy of its cryoablation systems?

The efficacy of IceCure鈥檚 systems is validated through rigorous clinical trials and studies presented at major medical conferences. Independent studies have consistently shown that their technology achieves high ablation success rates with minimal adverse events.

In what markets are IceCure鈥檚 products available?

IceCure鈥檚 ProSense庐 system and associated technologies are marketed globally, with regulatory approvals in key regions including the United States, Europe, China, and parts of Asia. This global presence underscores the company鈥檚 commitment to expanding access to innovative cryoablation therapies.

What role does intellectual property play in IceCure鈥檚 strategy?

A robust patent portfolio is central to IceCure鈥檚 strategy, protecting its innovations in cryoablation technology. The company continuously invests in research and development, ensuring its products remain at the forefront of the minimally invasive therapy market.

What benefits do patients experience with IceCure鈥檚 cryoablation treatment?

Patients benefit from a treatment option that is less invasive than traditional surgery, leading to reduced pain, lower risk of complications, and faster recovery times. This approach not only minimizes discomfort but also improves overall patient outcomes.
Icecure Medical Ltd.

NASDAQ:ICCM

ICCM Rankings

ICCM Stock Data

59.57M
30.74M
48.54%
0.27%
1.06%
Medical Devices
Healthcare
Israel
Caesarea